Overview

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Status:
Terminated

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene Corporation

Treatments:

Cetuximab
Lenalidomide
Thalidomide